How evidence-based are advertisements in journals regarding the subspecialty of rheumatology?

Rheumatology

Volumn 45, Issue 9, 2006, Pages 1154-1157

  van Winkelen, P ^a   van Denderen, J S ^a   Vossen, C Y ^a   Huizinga, T W J ^a,a   Dekker, F W ^a,a   van Adrichem, R A ^a   de Boer, M M ^a   Bruijn, M S ^a   Bruijn, D J ^a   Dijk, P D ^a   Hoppe, B P C ^a   Kortmann, C J ^a   van der Marel, S ^a   van de Merwe, A G ^a   van Rhenen, J ^a   Saadatmand, S ^a   Vennemann, V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advertisements; Evidence based; Rheumatology

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADVERTIZING; ARTICLE; EVIDENCE BASED PRACTICE; MEDICAL INFORMATION; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; RHEUMATOLOGY; SCORING SYSTEM;

ADVERTISING; ANTIRHEUMATIC AGENTS; DRUG INDUSTRY; EVIDENCE-BASED MEDICINE; HUMANS; PEER REVIEW; PERIODICALS; RHEUMATOLOGY;

EID: 33749628872     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel073     Document Type: Article

References (15)

1. Lankinen KS, Levola T, Marttinen K, Puumalainen I, Helin-Salmivaara A. Industry guidelines, laws and regulations ignored: Quality of drug advertising in medical journals. Pharmacoepidemiol Drug Saf 2004;13:789-95.
2. Gutknecht DR. Evidence-based advertising? A survey of four major journals. J Am Board Fam Pract 2001;14:197-200.
3. Villanueva P, Peiro S, Librero J, Pereiro I. Accuracy of pharmaceutical advertisements in medical journals. Lancet 2003;36:27-32.
4. Loke TW, Koh FC, Ward JE. Pharmaceutical advertisement claims in Australian medical publications. Med J Aust 2002;177:291-3.
5. Bhattacharyya T, Tornetta P 3rd, Healy WL, Einhorn TA. The validity of claims made in orthopaedic print advertisements. J Bone Joint Surg Am 2003;85A:1224-8.
6. Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: Experts' assessments. Ann Intern Med 1992;116:912-9.
7. Cooper RJ, Schriger DL. The availability of references and the sponsorship of original research cited in pharmaceutical advertisements. CMAJ 2005;172:487-91.
8. Lexchin J, Holbrook A. Methodologic quality and relevance of references in pharmaceutical advertisements in a Canadian medical journal. CMAJ 1994;151:47-54.
9. Sutherland AG, Craig N, Maffulli N, Brooksbank A, Moir JS. Accuracy of references in the orthopaedic literature. J Bone Joint Surg Br 2000;82:9-10.
10. WHO. Resolution WHA41.17 adopted by the Forty-first World Health Assembly, 13 May 1988. Geneve: World Health Organization, 1988. Available: At http://www.who.int/.
11. IFPMA. IFPMA code of pharmaceutical marketing practices. Geneva: International Federation of Pharmaceutical Manufacturers and Associations, 1994. Available at: http://www.ifpma.org.
12. Wofsy D. Living in a different world. Arthritis Rheum 2005;52:395-401.
13. Chalmers TC, Smith H Jr, Blackburn B et al. A method for assessing the quality of a randomized control trial. Control Clin Trials 1981;2:31-49.
14. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trial: Is blinding necessary? Control Clin Tials 1996;17:1-12.
15. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 2003;289:454-65.